← Back to headlines
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
AbbVie has announced its acquisition of Apogee Therapeutics for $10.9 billion in cash, aiming to bolster its immunology pipeline with next-generation inflammatory disease drugs. The deal caused Apogee's stock to surge significantly.
22 Jun, 11:11 — 22 Jun, 14:04
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (59/100)5 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left2
Left (2)
Yahoocnbc
Center2
Center (2)
FTbloomberg
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US4UK1
Sources
Showing 5 of 5 sources
bloombergHigh71d ago
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash - Bloomberg.com
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash Bloomberg.com
Read full article →FTVery High71d ago
AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
Drugmaker’s largest deal in more than half a decade comes amid surge of M&A in sector
Read full article →cnbcMostly Factual71d ago
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in more than five years.
Read full article →YahooMostly Factual71d ago
AbbVie to acquire Apogee Therapeutics in $10.9B deal
Read full article →seeking-alphaMixed71d ago
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Read full article →Coverage Timeline
First report: bloomberg · 22 Jun, 11:11|Full coverage: 5 · 3h|Window: 3h
Left-leaningCenterRight-leaning
Related Stories
US-Iran Military Escalation Sparks Retaliatory Strikes and Market Volatility
27m ago
BP Appoints Ian Tyler as New Chairman Following Leadership Transition
33m ago
Everus Construction and California Resources Finalize Major Corporate Acquisitions
51m ago
Nvidia Nears $14 Billion Acquisition of AI Startup Hugging Face
1h ago